Antipsychotics-related hyperprolactinaemia among patients with schizophrenia in Maiduguri.

Autor:	Shettima FB; Department of Mental Health, Faculty of Psychiatry, Federal Neuropsychiatric Hospital, Maiduguri, Nigeria., Wakil MA; Department of Mental Health, Faculty of Psychiatry, University of Maiduguri Teaching Hospital, Maiduguri, Nigeria., Sheikh TL; Department of Mental Health, Faculty of Psychiatry, Ahmadu Bello University Zaria, Kaduna, Nigeria., Abdulaziz M; Department of Mental Health, Faculty of Psychiatry, Federal Neuropsychiatric Hospital Kaduna, Kaduna, Nigeria., Wakawa IA; Department of Mental Health, Faculty of Psychiatry, University of Maiduguri Teaching Hospital, Maiduguri, Nigeria., Beida O; Department of Mental Health, Faculty of Psychiatry, Federal Neuropsychiatric Hospital Kaduna, Kaduna, Nigeria.
Jazyk:	angličtina
Zdroj:	The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa [S Afr J Psychiatr] 2024 Feb 01; Vol. 30, pp. 2133. Date of Electronic Publication: 2024 Feb 01 (Print Publication: 2024).
DOI:	10.4102/sajpsychiatry.v30i0.2133
Abstrakt:	Background: Hyperprolactinaemia among patients on antipsychotic medications is generally overlooked due to lack of outwardly visible symptoms, patient resistance to reporting because the symptoms are perceived as shameful, or to clinician's insufficient knowledge. Aim: The study aimed to evaluate the patterns and correlates of hyperprolactinemia among patients with schizophrenia on antipsychotic medications. Setting: The study was conducted in a psychiatric facility in Maiduguri, Northeastern Nigeria. Methods: A total of 209 patients with schizophrenia were evaluated through a cross-sectional design and assayed for serum prolactin with ELISA Kits. Frequencies and percentages were tabulated for categorical variables. Variables with significant associations with hyperprolactinaemia on chi-square ( p < 0.05) were subjected to logistic regression analysis. Results: The prevalence of hyperprolactinaemia was 45.9% in all patients on antipsychotic medication. The prevalence because of the use of typical and atypical antipsychotics was 51.5% and 25.0%, respectively. Hyperprolactinaemia was significantly associated with typical antipsychotics (β = 0314, p = 0.002), high overall drug dosage (β = 2.340, p = 0.003), high-dose typical antipsychotics (β = 3.228, p = 0.000), twice daily dosing frequency (β = 2.751, p = 0.001) and polypharmacy (β = 1.828, p = 0.0024). Conclusion: The findings support that patients on typical, high-dose antipsychotic medications and polypharmacy have a high prevalence of hyperprolactinaemia. As hyperprolactinaemia is often undetectable, screening and patient psycho-education on the significance of the signs and symptoms of hyperprolactinaemia is required for necessary clinical intervention. Contribution: The study provides evidence for the rational use of antipsychotic medications in sub-Saharan Africa. Competing Interests: The authors have declared that no competing interest exist. (© 2024. The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu